Romvimza (vimseltinib) — CareFirst (Caremark)
Tenosynovial giant cell tumor (TGCT)
Initial criteria
- Member has measurable disease (a lesion of at least 2 centimeters)
- Member is not a candidate for surgical resection
Reauthorization criteria
- Member demonstrates clinical benefit (e.g., decreased tumor volume score, improvement in range of motion of the affected joint, or improvement of pain scores)
- No evidence of unacceptable toxicity while on the current regimen
Approval duration
12 months